Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

SK Bioscience (302440 KS): Solid Growth Centered on IDT in 1Q; Operating Loss Widened

SK Bioscience (302440 KS): IDT Drives Strong 3Q Performance; Operating Loss Narrows

SK Bioscience (302440 KS): Strong Base Business and IDT Contribution Drive 2Q25 Performance

SK Bioscience (302440 KS): Dual Engines Led Growth Strategy Is on Track; Solid 1Q25 Performance

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sk-bioscience-co-ltd" target="_blank" data-smartkarma-citation="entities:31484:1" rel="noopener">SK Bioscience (302440 KS)</a> ended 2025 with revenue of KRW651B, up 144% YoY, topping guidance of KRW600B, driven by both base business and IDT. IDT contributed KRW466B (up 17% YoY).</li>
<li>Despite continued large-scale investments in R&amp;D and manufacturing facilities, SKBS reduced 2025 operating losses to KRW124B from KRW138B in 2024, reflecting increased contributions from IDT and growth across key products.</li>
<li>The company in-licensed Phase 1a-complete RSV antibody RSM01 from Gates MRI. Backed by global exclusive supply rights, RSM01is positioned as new growth driver targeting global addressable market of ~KRW6T.</li>
</ul>



SK Bioscience (302440 KS) ended 2025 with revenue of KRW651B, up 144% YoY, topping guidance of KRW600B, driven by both base business and IDT. IDT contributed KRW466B (up 17% YoY).
Despite continued large-scale investments in R&amp;D and manufacturing facilities, SKBS reduced 2025 operating losses to KRW124B from KRW138B in 2024, reflecting increased contributions from IDT and growth across key products.
The company in-licensed Phase 1a-complete RSV antibody RSM01 from Gates MRI. Backed by global exclusive supply rights, RSM01is positioned as new growth driver targeting global addressable market of ~KRW6T.


SK Bioscience (302440 KS): Base Business Revives; IDT Turnaround; Preparing for a Leap Toward